arrow
K

Kazuya Shimoda

medicine
H指数:50
被引数:1.1万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Molecular Response, Event-Free Survival, and Treatment-Free Remission in Myeloproliferative Neoplasms: Update and Review with Insights from MPN Asia 2026

分子应答、无事件生存和治疗后缓解在骨髓增殖性肿瘤中的应用:更新与综述及MPN Asia 2026的见解

2026-09-180
OAAI
Ropeginterferon alfa-2b in hydroxyurea-intolerant or hydroxyurea-refractory essential thrombocythaemia (SURPASS ET): a multicentre, open-label, randomised, active-controlled, phase 3 study

罗培干扰素alfa-2b在羟基脲不耐受或羟基脲难治性原发性血小板增多症(SURPASS ET):一项多中心、开放标签、随机、活性对照、III期研究

2025-11-030
PRE
Prognostic value of lymphocyte-to-monocyte ratio in relapsed/refractory adult T-cell Leukemia/lymphoma patients receiving mogamulizumab

淋巴细胞与单核细胞比值在复发/难治性成人T细胞白血病/淋巴瘤患者接受mogamulizumab治疗中的预后价值

2025-10-300
PRE
Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms

MPN Asia 2025亮点:髓系增殖性肿瘤的分子发病机制和治疗策略进展

2025-07-120
OA
Impact of Cooperating Myeloid Gene Mutations on Disease Progression and Survival in Japanese MPN Patients: A Multicenter Study

合作髓系基因突变对日本MPN患者疾病进展和生存的影响:一项多中心研究

BLOOD
IF23.1
2024-11-050
PRE
HOPE-PMF: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study to Assess Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Early/Lower-Risk Primary Myelofibrosis

HOPE-PMF:一项随机、双盲、安慰剂对照的3期研究,旨在评估罗培干扰素α-2b在早期/低风险原发性骨髓纤维化患者中的有效性和安全性

BLOOD
IF23.1
2024-11-050
PRE
A Phase 1/2 Study of Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor, in Combination with JAK Inhibitors Ruxolitinib or Momelotinib in Patients with Myelofibrosis

一项关于Nuvisertib(TP-3654)的1/2期研究,Nuvisertib是一种实验性选择性PIM1激酶抑制剂,与JAK抑制剂Ruxolitinib或Momelotinib联合用于骨髓纤维化患者。

BLOOD
IF23.1
2024-11-051
PRE
Cytokine Modulation Correlates Strongly with Symptom Improvement in Patients with Myelofibrosis Treated with Nuvisertib (TP-3654), an Investigational Selective PIM1 Kinase Inhibitor

细胞因子调节与接受Nuvisertib(TP-3654)治疗骨髓纤维化患者的症状改善显著相关,Nuvisertib是一种在研的选择性PIM1激酶抑制剂。

BLOOD
IF23.1
2024-11-050
PRE
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis (JUL, 10.1007/s00277-024-05898-3, 2024)
2024-08-210
OA
Predictive significance of high neutrophil ratio for thrombosis in myeloproliferative neoplasms: JSH-MPN-R18 subanalysis
2024-07-221
PRE
Impaired humoral immunity following COVID-19 vaccination in HTLV-1 carriers
2024-01-173
OAAI
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis

原发性血小板增多症后和真性红细胞增多症后骨髓纤维化的真实临床特征

2023-11-101
PRE
Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model
2023-07-197
OAAI